Targovax has hired Oystein Soug to serve as the company’s chief financial officer, effective June 1.
Soug’s experience includes 17 years in corporate development and international finance. Since 2013, he has been the director and deputy chairman of Bionor Pharma ASA.
“With Oystein in place we are well-positioned to move our products through the important proof of concept phase," Targovax CEO Gunnar Gardemyr said. "Oystein's recent experience from the successful financing and subsequent sale of Algeta to Bayer will be important to develop Targovax further."
Soug has also worked as Algeta ASA's CFO since 2008 as the company increased its capital by $200 million, improved sales and production in the U.S., merged with Bayer AG, and began Xofigo. He previously worked with the Norwegian Orkla group, where he served as the project manager of Orkla’s Corporate Development mergers and acquisitions team before serving as the CFO of SladCo, Orkla’s Russian operations branch.
Soug earned graduate degrees in economics, finance and international management from Switzerland’s University of St. Gallen.